Addressing Therapeutic Inhibition in the Heart Failure Therapy

[摘要] A survival rate of 50% for Heart Failure (HF) with decreased ejection fraction HFrEF five years following diagnosis is comparable to that ofmany malignancies. Fortunately, there are now a number of approved oral drugs that have been shown to lower the risk of death and HFhospitalization while also enhancing patient-reported quality of life. Angiotensin Receptor-Neprilysin Inhibitor (ARNI), beta-blocker,Mineralocorticoid Receptor Antagonist (MRA) and Sodium Glucose co-transporter-2 inhibitor SGT2-i have been shown to have acumulative effect on comprehensive disease-modifying quadruple therapy that includes a 73% relative reduction in risk of death over twoyears. Although fewer than 1 in 4 eligible patients are given triple therapy with ACEI/ARB/ARNI, beta-blocker, and MRA, and adoption ofSGLT2-i is anticipated to be delayed, there are significant gaps in the use of Guideline-Directed Medical Therapy (GDMT) in real-world USpractice [1].

[学科分类] 药理学